Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,782,416 papers from all fields of science
Search
Sign In
Create Free Account
agalsidase beta
Known as:
agalsidase beta [Chemical/Ingredient]
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
7 relations
Broader (2)
ALPHA-D-GALACTOSIDASE ENZYME
Isoenzymes
Alpha-glucosidase
Drug Allergy
Fabry Disease
analogs & derivatives
Narrower (1)
Fabrazyme
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Improvement of Fabry Disease-Related Gastrointestinal Symptoms in a Significant Proportion of Female Patients Treated with Agalsidase Beta: Data from the Fabry Registry.
W. Wilcox
,
U. Feldt-Rasmussen
,
+8 authors
R. Hopkin
JIMD reports
2018
Corpus ID: 4521718
Fabry disease, an X-linked inherited lysosomal storage disorder, is caused by mutations in the gene encoding α-galactosidase, GLA…
Expand
Review
2017
Review
2017
Switch to agalsidase alfa after shortage of agalsidase beta in Fabry disease: a systematic review and meta-analysis of the literature
A. Pisani
,
D. Bruzzese
,
M. Sabbatini
,
L. Spinelli
,
M. Imbriaco
,
E. Riccio
Genetics in Medicine
2017
Corpus ID: 5121764
Background:In 2009, the agalsidase beta shortage resulted in switching to agalsidase alfa treatment for many Fabry disease…
Expand
Highly Cited
2012
Highly Cited
2012
Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation
D. Warnock
,
A. Ortiz
,
+13 authors
C. Wanner
Nephrology, dialysis, transplantation : official…
2012
Corpus ID: 988815
Background. The purpose of this study was to identify determinants of renal disease progression in adults with Fabry disease…
Expand
Review
2012
Review
2012
Agalsidase alfa: a review of its use in the management of Fabry disease.
G. Keating
BioDrugs : clinical immunotherapeutics…
2012
Corpus ID: 40445936
The enzyme replacement therapy agalsidase alfa (Replagal®) has an amino acid sequence identical to that of native α-galactosidase…
Expand
Review
2012
Review
2012
Agalsidase Alfa
G. Keating
BioDrugs
2012
Corpus ID: 18624007
The enzyme replacement therapy agalsidase alfa (Replagal®) has an amino acid sequence identical to that of native α-galactosidase…
Expand
2011
2011
Role of cardiac MRI in evaluating patients with Anderson-Fabry disease: assessing cardiac effects of long-term enzyme replacement therapy
G. Messalli
,
M. Imbriaco
,
+7 authors
A. Pisani
La radiologia medica
2011
Corpus ID: 28723709
PurposeAnderson-Fabry disease is a multisystemic disorder of lipid metabolism secondary to X-chromosome alterations and is…
Expand
Review
2010
Review
2010
Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: Findings from the Fabry Registry
T. Watt
,
A. Burlina
,
+8 authors
U. Feldt-Rasmussen
Genetics in Medicine
2010
Corpus ID: 23666715
Disclosure: The Fabry Registry is sponsored by Genzyme Corporation. U.F.-R., K.S., R.J.H., M.B., A.M., and A.P.B. serve on the…
Expand
Review
2007
Review
2007
Agalsidase-Beta Therapy for Advanced Fabry Disease
M. Banikazemi
,
J. Bultas
,
+8 authors
R. Desnick
Annals of Internal Medicine
2007
Corpus ID: 26003953
Context Fabry disease is an X-linked storage disorder characterized by deficient lysosomal enzyme activity and excessive…
Expand
Highly Cited
2005
Highly Cited
2005
Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy.
M. Banikazemi
,
T. Ullman
,
R. Desnick
Molecular genetics and metabolism
2005
Corpus ID: 45906565
Review
2004
Review
2004
Clinical benefit in Fabry patients given enzyme replacement therapy—A case series
N. Guffon
,
A. Fouilhoux
Journal of Inherited Metabolic Disease
2004
Corpus ID: 43018297
Summary: Fabry disease is a rare lysosomal storage disorder resulting from deficient activity of α-galactosidase A and subsequent…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE